Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Two Dose-Arm, Parallel Study of the Safety and Effectiveness of Immune Globulin Intravenous (Human), 10 percent (IGIV, 10 percent) for the Treatment of Mild to Moderate Alzheimer's Disease.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 10 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

05 Apr 2017 Results assessing safety and efficacy of Immune-globulin in ITT population and subgroups, published in the Neurology
16 Jul 2013 Results presented at the 2013 Alzheimer's Association International Conference .
16 Jul 2013 Positive data from cognition and biomarker tests presented at the Alzheimer's Association International Conference 2013 (AAIC 2013), according to a Baxter International media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com